BioStock: Stayble Therapeutics presents phase IIb data within one month

Stayble Therapeutics is facing the company’s most important milestone to date, presenting top-line data from the phase IIb study with STA363 in patients with degenerative disc disease. The results from the phase IIb study are expected to be presented in November or at the latest in early December. Subject to positive results, the company plans to intensify partnering activities in collaboration with the transaction advisor Ferghana Partners. 

Read the full article at biostock.se:

https://www.biostock.se/en/2023/11/stayble-therapeutics-presents-phase-iib-data-within-one-month/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se